BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 36858337)

  • 1. Risk of medication-related osteonecrosis of the jaw after dental extractions in patients receiving antiresorptive agents - A retrospective study of 240 patients.
    Coropciuc R; Coopman R; Garip M; Gielen E; Politis C; Van den Wyngaert T; Beuselinck B
    Bone; 2023 May; 170():116722. PubMed ID: 36858337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interventions for managing medication-related osteonecrosis of the jaw.
    Beth-Tasdogan NH; Mayer B; Hussein H; Zolk O
    Cochrane Database Syst Rev; 2017 Oct; 10(10):CD012432. PubMed ID: 28983908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medication-related osteonecrosis of the jaw: risk factors in patients under biphosphonate versus patients under antiresorptive-antiangiogenic drugs.
    Ghidini G; Manfredi M; Giovannacci I; Mergoni G; Sarraj A; Mureddu M; Giunta G; Bonanini M; Meleti M; Vescovi P
    Minerva Stomatol; 2017 Aug; 66(4):135-140. PubMed ID: 28497661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multicenter retrospective study of the risk factors associated with medication-related osteonecrosis of the jaw after tooth extraction in patients receiving oral bisphosphonate therapy: can primary wound closure and a drug holiday really prevent MRONJ?
    Hasegawa T; Kawakita A; Ueda N; Funahara R; Tachibana A; Kobayashi M; Kondou E; Takeda D; Kojima Y; Sato S; Yanamoto S; Komatsubara H; Umeda M; Kirita T; Kurita H; Shibuya Y; Komori T;
    Osteoporos Int; 2017 Aug; 28(8):2465-2473. PubMed ID: 28451732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Prevention of Medication-related Osteonecrosis of the Jaw.
    Poxleitner P; Engelhardt M; Schmelzeisen R; Voss P
    Dtsch Arztebl Int; 2017 Feb; 114(5):63-69. PubMed ID: 28241916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dental pathologies in tumor patients with bone metastases or multiple myeloma scheduled for antiresorptive therapy.
    Laimer J; Hechenberger M; Müller D; Walch B; Kolk A; Schnabl D; Schomaker M; Bruckmoser E
    Future Oncol; 2021 Jul; 17(21):2705-2711. PubMed ID: 33880956
    [No Abstract]   [Full Text] [Related]  

  • 7. Incidence and risk factors associated to Medication-Related Osteo Necrosis of the Jaw (MRONJ) in patients with osteoporosis after tooth extractions. A 12-months observational cohort study.
    Cuozzo A; Iorio-Siciliano V; Vaia E; Mauriello L; Blasi A; Ramaglia L
    J Stomatol Oral Maxillofac Surg; 2022 Nov; 123(6):616-621. PubMed ID: 35609780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence and trend of antiresorptive agent-related osteonecrosis of the jaw from 2016 to 2020 in Kure, Japan.
    Kunihara T; Tohmori H; Tsukamoto M; Kobayashi M; Okumura T; Teramoto H; Hamasaki T; Yamasaki T; Nakagawa T; Okimoto N; Fujiwara S
    Osteoporos Int; 2023 Jun; 34(6):1101-1109. PubMed ID: 37002373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medication-Related Osteonecrosis of the Jaws in the Pediatric Population.
    Neal TW; Schlieve T
    J Oral Maxillofac Surg; 2022 Oct; 80(10):1686-1690. PubMed ID: 35931181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osteonecrosis of the Jaw and Antiresorptive Agents in Benign and Malignant Diseases: A Critical Review Organized by the ECTS.
    Anastasilakis AD; Pepe J; Napoli N; Palermo A; Magopoulos C; Khan AA; Zillikens MC; Body JJ
    J Clin Endocrinol Metab; 2022 Apr; 107(5):1441-1460. PubMed ID: 34922381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Position paper on medication-related osteonecrosis of the jaw (MRONJ)].
    Svejda B; Muschitz Ch; Gruber R; Brandtner Ch; Svejda Ch; Gasser RW; Santler G; Dimai HP
    Wien Med Wochenschr; 2016 Feb; 166(1-2):68-74. PubMed ID: 26847441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A real-world study on the prevalence and risk factors of medication related osteonecrosis of the jaw in cancer patients with bone metastases treated with Denosumab.
    Bracchi P; Zecca E; Brunelli C; Miceli R; Tinè G; Maniezzo M; Lo Dico S; Caputo M; Shkodra M; Caraceni AT
    Cancer Med; 2023 Sep; 12(17):18317-18326. PubMed ID: 37559413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary wound closure after tooth extraction for prevention of medication-related osteonecrosis of the jaw in patients under denosumab.
    Matsumoto A; Sasaki M; Schmelzeisen R; Oyama Y; Mori Y; Voss PJ
    Clin Oral Investig; 2017 Jan; 21(1):127-134. PubMed ID: 26924135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medication-related osteonecrosis of the jaw: Prevention, diagnosis and management in patients with cancer and bone metastases.
    Otto S; Pautke C; Van den Wyngaert T; Niepel D; Schiødt M
    Cancer Treat Rev; 2018 Sep; 69():177-187. PubMed ID: 30055439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Both non-surgical dental treatment and extractions increase the risk of medication-related osteonecrosis of the jaw: case-control study.
    McGowan K; Ware RS; Acton C; Ivanovski S; Johnson NW
    Clin Oral Investig; 2019 Nov; 23(11):3967-3975. PubMed ID: 30747305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A 5-year retrospective cohort study of denosumab induced medication related osteonecrosis of the jaw in osteoporosis patients.
    Jung S; Kim J; Park JH; Kim KY; Kim HJ; Park W
    Sci Rep; 2022 May; 12(1):8641. PubMed ID: 35606457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endodontic treatment of odontogenic infection in a patient at risk of medication-related osteonecrosis of the jaw: a case report and review of treatment criteria.
    Ferrari CR; Maciel AP; Quispe RA; Betti LV; Duarte MAH; da Silva Santos PS
    Gen Dent; 2023; 71(4):72-76. PubMed ID: 37358587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osteonecrosis of the jaws in patients under osteoporosis treatment: a nine-year experience report.
    Penoni DC; Canellas JVS; Silami MANC; Sader F; Pimentel GS; Leão ATT
    Arch Endocrinol Metab; 2023 May; 67(4):e000612. PubMed ID: 37252700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does inflammatory dental disease affect the development of medication-related osteonecrosis of the jaw in patients using high-dose bone-modifying agents?
    Ueda N; Nakashima C; Aoki K; Shimotsuji H; Nakaue K; Yoshioka H; Kurokawa S; Imai Y; Kirita T
    Clin Oral Investig; 2021 May; 25(5):3087-3093. PubMed ID: 33057886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk-reductive dental strategies for medication related osteonecrosis of the jaw among cancer patients: A systematic review with meta-analyses.
    Karna H; Gonzalez J; Radia HS; Sedghizadeh PP; Enciso R
    Oral Oncol; 2018 Oct; 85():15-23. PubMed ID: 30220314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.